Base de dados : LILACS
Pesquisa : D02.065.884 [Categoria DeCS]
Referências encontradas : 161 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 17 ir para página                         

  1 / 161 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1292435
Autor: Lorenzini G, María Josefina; Kutscher C, Sofía; González F, María José; Fuenzalida P, Magdalena; Pizarro R, Margarita; Díaz P, Luis Antonio; Riquelme P, Arnoldo.
Título: Régimen basado en Vonoprazan es más efectivo que el basado en inhibidores de la bomba de protones como primera línea en la erradicación de Helicobacter pylori: estudio clínico randomizado / Vonoprazan-based regimen is more useful than PPI-based one as a first-line helicobacter pylori rradication: a randomized controlled trial
Fonte: Gastroenterol. latinoam;31(2):107-112, 2020. tab.
Idioma: es.
Descritores: Pirróis/uso terapêutico
Sulfonamidas/uso terapêutico
Helicobacter pylori
Infecções por Helicobacter/tratamento farmacológico
Inibidores da Bomba de Prótons/uso terapêutico
Limites: Humanos
Responsável: CL61.1 - Biblioteca Central Campus Sur


  2 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-785727
Autor: Maldonado-Avila, Miguel; Garduño-Arteaga, Leopoldo; Jungfermann-Guzman, Rene; Manzanilla-Garcia, Hugo A; Rosas-Nava, Emmanuel; Procuna-Hernandez, Nestor; Vela-Mollinedo, Alejandro; Almazan-Treviño, Luis; Guzman-Esquivel, Jose.
Título: Efficacy of Tamsulosin, Oxybutynin, and their combination in the control of double-j stent-related lower urinary tract symptoms
Fonte: Int. braz. j. urol;42(3):487-493tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction and objective Indwelling double J ureteral stents are used routinely in the resolution of ureteral obstruction caused by different etiologies. Evaluation of urinary symptoms related to double-J stent, indicate that these affect 73-90% of patients. We conducted a prospective, randomized study, to evaluate the efficacy of tamsulosin, oxybutinin and combination therapy in improving the urinary symptoms. Methods Patients who underwent ureteral stent placement after ureterolithotripsy (total 51), were randomized into three groups: Group I: Tamsulosin 0.4 mg. once per day(17 patients), Group II: Oxybutinin 5 mg. once per day (17 patients), Group III: Tamsulosin+ oxybutynin once per day (17 patients). All the groups received the drugs for three weeks and completed a Spanish validated Ureteral Stent Symptom Questionnaire (USSQ) at day 7 and 21. Results Repeated measures ANOVA showed mean urinary symptom index score was 22.3 vs. 15.5 in group three (p<0.001) at day 7 and 21 respectively. The mean work performance index was 6.6 vs 8.1 (p=0.049) favoring tamsulosin group, the mean sexual score was 0.5 vs 1.5 (p=0.03). Among additional problems the mean was 7.2 vs 6.2 (p=0.03). No significant difference was noted among pain and general health index. No side effects were reported. Conclusions Combination therapy with tamsulosin and oxybutynin improved irritative symptoms and work performance as well as sexual matters. Combination therapy should be considered for patients who complained of stent related symptoms.
Descritores: Sulfonamidas/uso terapêutico
Stents/efeitos adversos
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Agentes Urológicos/uso terapêutico
Ácidos Mandélicos/uso terapêutico
-Qualidade de Vida
Fatores de Tempo
Ureter
Obstrução Ureteral
Obstrução Ureteral/complicações
Obstrução Ureteral/terapia
Método Simples-Cego
Estudos Prospectivos
Inquéritos e Questionários
Reprodutibilidade dos Testes
Análise de Variância
Resultado do Tratamento
Quimioterapia Combinada
Sintomas do Trato Urinário Inferior/prevenção & controle
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adulto
Tipo de Publ: Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  3 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-785721
Autor: Akkoc, Ali; Aydin, Cemil; Topaktas, Ramazan; Kartalmis, Mahir; Altin, Selcuk; Isen, Kenan; Metin, Ahmet.
Título: Prophylactic effects of alpha-blockers, Tamsulosin and Alfuzosin, on postoperative urinary retention in male patients undergoing urologic surgery under spinal anaesthesia
Fonte: Int. braz. j. urol;42(3):578-584tab.
Idioma: en.
Resumo: ABSTRACT Purpose Postoperative urinary retention (POUR) is one of the most common complications after surgical procedures under spinal anaesthesia. Recent studies have shown the beneficial effects of alpha-adrenergic blockers in preventing POUR. The aim of this prospective study was to investigate and compare the prophylactic effects of tamsulosin and alfuzosin on POUR after urologic surgical procedures under spinal anaesthesia. Materials and Methods A total of 180 males who underwent elective urologic surgery were included in this study. The patients were randomly allocated into three Groups. The Group I received placebo. Patients in Group II were given 0.4mg of tamsulosin orally 14 and 2 hours before surgery. Patients in Group III were given 10mg of alfuzosin ER orally 10 and 2 hours before surgery. All patients were closely followed for 24 hours postoperatively and their episodes of urinary retentions were recorded. Results There were 60 patients in each Group. Their mean age was 35.95±15.16 years. Fifteen patients in Group I (25%), 3 patients in Group II (5%) and 4 patients in Group III (6.7%) required catheterization because of urinary retention. In tamsulosin group and alfuzosin group, there were a significantly lower proportion of patients with POUR compared with the placebo Group (p=0.002 and p=0.006). The beneficial effects of tamsulosin and alfuzosin on POUR were similar between both Groups (p=0.697). Conclusion This study suggests that the use of prophylactic tamsulosin or alfuzosin can reduce the incidence of urinary retention and the need for catheterization after urologic surgical procedures under spinal anaesthesia.
Descritores: Quinazolinas/uso terapêutico
Sulfonamidas/uso terapêutico
Procedimentos Cirúrgicos Urológicos Masculinos/efeitos adversos
Retenção Urinária/prevenção & controle
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Profilaxia Pré-Exposição/métodos
Raquianestesia/efeitos adversos
-Complicações Pós-Operatórias/prevenção & controle
Fatores de Tempo
Cateterismo Urinário
Estudos Prospectivos
Reprodutibilidade dos Testes
Análise de Variância
Retenção Urinária/etiologia
Resultado do Tratamento
Tansulosina
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Adolescente
Adulto
Idoso
Adulto Jovem
Tipo de Publ: Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  4 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-777316
Autor: Zhu, Jianguo; Liang, Yuxiang; Chen, Weihong; Xu, Shuxiong; Wang, Yuanlin; Hu, Jianxing; He, Hui-chan; Zhong, Wei-de; Sun, Zhaolin.
Título: Effect of alpha1-blockers on stentless ureteroscopic lithotripsy
Fonte: Int. braz. j. urol;42(1):101-106, Jan.-Feb. 2016. tab.
Idioma: en.
Projeto: NationalNatural Science Foundation of China.
Resumo: ABSTRACT Objective To evaluate the clinical efficiency of alpha1-adrenergic antagonists on stentless ureteroscopic lithotripsy treating uncomplicated lower ureteral stones. Materials and Methods From January 2007 to January 2013, 84 patients who have uncomplicated lower ureteral stones treated by ureteroscopic intracorporeal lithotripsy with the holmium laser were analyzed. The patients were divided into two groups, group A (44 patients received indwelled double-J stents) and group B (40 patients were treated by alpha1-adrenergic antagonists without stents). All cases of group B were treated with alpha1 blocker for 1 week. Results The mean operative time of group A was significantly longer than group B. The incidences of hematuria, flank/abdominal pain, frequency/urgency after surgery were statistically different between both groups. The stone-free rate of each group was 100%. Conclusions The effect of alpha1-adrenergic antagonists is more significant than indwelling stent after ureteroscopic lithotripsy in treating uncomplicated lower ureteral stones.
Descritores: Sulfonamidas/uso terapêutico
Litotripsia/métodos
Cálculos Ureterais/cirurgia
Ureteroscopia/métodos
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
-Complicações Pós-Operatórias
Período Pós-Operatório
Medição da Dor
Estudos Prospectivos
Reprodutibilidade dos Testes
Resultado do Tratamento
Estatísticas não Paramétricas
Lasers de Estado Sólido/uso terapêutico
Duração da Cirurgia
Tansulosina
Tempo de Internação
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adulto
Adulto Jovem
Tipo de Publ: Estudo de Validação
Responsável: BR1.1 - BIREME


  5 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-954052
Autor: Demir, Mehmet; Akin, Yigit; Terim, Kubra Asena Kapakin; Gulum, Mehmet; Buyukfirat, Evren; Ciftci, Halil; Yeni, Ercan.
Título: Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study
Fonte: Int. braz. j. urol;44(3):600-607, May-June 2018. tab, graf.
Idioma: en.
Projeto: Harran University Scientific Research and Projects Unit.
Resumo: ABSTRACT Objectives: Apoptosis effect of oral alpha-blockers is known in the prostate. Apoptosis index of silodosin has not been proved, yet. Aims are to present apoptosis index of silodosin in prostate and to compare this with other currently used alpha-blocker's apoptosis indexes together with their clinical effects. Materials and Methods: Benign prostatic hyperplasia (BPH) patients were enrolled among those admitted to urology outpatient clinic between June 2014 and June 2015. Study groups were created according to randomly prescribed oral alpha-blocker drugs as silodosin 8mg (Group 1; n=24), tamsulosin 0.4mg (Group 2; n=30), alfuzosin 10mg (Group 3; n=25), doxazosin 8mg (Group 4; n=22), terazosin 5mg (Group 5; n=15). Pa- tients who refused to use any alpha-blocker drug were included into Group 6 as control group (n=16). We investigated apoptosis indexes of the drugs in prostatic tissues that were taken from patient's surgery (transurethral resection of prostate) and/or prostate biopsies. Immunochemical dyeing, light microscope, and Image Processing and Analy- sis in Java were used for evaluations. Statistical significant p was p<0.05. Results: There were 132 patients with mean follow-up of 4.2±2.1 months. Pathologist researched randomly selected 10 areas in each microscope set. Group 1 showed statisti- cal significant difference apoptosis index in immunochemical TUNEL dyeing and im- age software (p<0.001). Moreover, we determined superior significant development in parameters as uroflowmetry, quality of life scores, and international prostate symptom score in Group 1. Conclusions: Silodosin has higher apoptosis effect than other alpha-blockers in prostate. Thus, clinic improvement with silodosin was proved by histologic studies. Besides, static factor of BPH may be overcome with creating apoptosis.
Descritores: Próstata/efeitos dos fármacos
Próstata/patologia
Hiperplasia Prostática/patologia
Hiperplasia Prostática/tratamento farmacológico
Apoptose/efeitos dos fármacos
Antagonistas de Receptores Adrenérgicos alfa 1/farmacologia
-Quinazolinas/farmacologia
Valores de Referência
Sulfonamidas/farmacologia
Fatores de Tempo
Biópsia
Prazosina/análogos & derivados
Prazosina/farmacologia
Imuno-Histoquímica
Projetos Piloto
Estudos Retrospectivos
Resultado do Tratamento
Antígeno Prostático Específico/sangue
Doxazossina/farmacologia
Tansulosina
Indóis/farmacologia
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  6 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-950723
Autor: Rosas, Carlos; Sinning, Mariana; Ferreira, Arturo; Fuenzalida, Marcela; Lemus, David.
Título: Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy
Fonte: Biol. Res;47:1-9, 2014. ilus, graf.
Idioma: en.
Projeto: Fondo Nacional de Desarrollo Científico y Tecnológico, Chile.
Resumo: BACKGROUND: During the last few years it has been shown in several laboratories that Celecoxib (Cx), a non-steroidal anti-inflammatory agent (NSAID) normally used for pain and arthritis, mediates antitumor and antiangiogenic effects. However, the effects of this drug on a tumor cell line resistant to chemotherapeutical drugs used in cancer have not been described. Herein we evaluate the angiogenic and antitumor effects of Cx in the development of a drug-resistant mammary adenocarcinoma tumor (TA3-MTXR). RESULTS: Cx reduces angiogenesis in the chick embryonic chorioallantoic membrane assay (CAM), inhibits the growth and microvascular density of the murine TA3-MTXR tumor, reduces microvascular density of tumor metastases, promotes apoptosis and reduces vascular endothelial growth factor (VEGF) production and cell proliferation in the tumor. CONCLUSION: The antiangiogenic and antitumor Cx effects correlate with its activity on other tumor cell lines, suggesting that Prostaglandins (PGs) and VEGF production are involved. These results open the possibility of using Celecoxib combined with other experimental therapies, ideally aiming to get synergic effects.
Descritores: Pirazóis/farmacologia
Sulfonamidas/farmacologia
Neoplasias da Mama/tratamento farmacológico
Anti-Inflamatórios não Esteroides/farmacologia
Apoptose/efeitos dos fármacos
Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos
Neoplasias Pulmonares/secundário
Neovascularização Patológica/tratamento farmacológico
-Pirazóis/administração & dosagem
Sulfonamidas/administração & dosagem
Neoplasias da Mama/patologia
Ensaios de Seleção de Medicamentos Antitumorais
Galinhas
Marcação In Situ das Extremidades Cortadas
Inibidores da Angiogênese/farmacologia
Linhagem Celular Tumoral
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
Membrana Corioalantoide
Proliferação de Células/efeitos dos fármacos
Celecoxib
Limites: Animais
Feminino
Embrião de Galinha
Camundongos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: CL1.1 - Biblioteca Central


  7 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1134321
Autor: Ouyang, Wei; Sun, Guoliang; Long, Gongwei; Liu, Man; Xu, Hua; Chen, Zhiqiang; Ye, Zhangqun; Li, Heng; Zhang, Yucong.
Título: Adjunctive medical expulsive therapy with tamsulosin for repeated extracorporeal shock wave lithotripsy: a systematic review and meta-analysis
Fonte: Int. braz. j. urol;47(1):23-35, Jan.-Feb. 2021. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: To evaluate the efficacy of adjunctive medical expulsive therapy (MET) with tamsulosin for the promotion of stone fragments clearance for repeated extracorporeal shock wave lithotripsy (ESWL). Materials and Methods: This meta-analysis was conducted by systematic search for randomized controlled trial (RCT) studies in PubMed/Medline, Scopus, Cochrane Library, Web of Science databases in January 2020, which compared tamsulosin with either placebo or non-placebo control for repeated ESWL. The primary endpoint was stone-free rate (SFR), the second endpoints were stone clearance time and complications. The quality assessment of included studies was performed by using the Cochrane System and Jadad score. Results: 7 RCTs were included in this meta-analysis. Tamsulosin provided higher SFR (for stones larger than 1cm, OR: 5.56, p=0.0003), except for patients with stones less than 1cm. For patients with renal stones (OR: 2.97, p=0.0005) or upper ureteral stones (OR: 3.10, p=0.004), tamsulosin can also provide a higher SFR. In addition, tamsulosin provided a shorter stone clearance time (WMD: −9.40, p=0.03) and lower pain intensity (WMD=-17.01, p <0.0001) and incidences of steinstrasse (OR: 0.37, p=0.0002). Conclusion: Adjunctive MET with tamsulosin is effective in patients with specific stone size or location that received repeated ESWL. However, no well-designed RCT that used computed tomography for the detection and assessment of residual stone fragments was found. More studies with high quality and the comparison between tamsulosin and secondary ESWL are needed in the future.
Descritores: Litotripsia
Cálculos Renais/terapia
Cálculos Ureterais/tratamento farmacológico
-Sulfonamidas/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
Tansulosina
Limites: Humanos
Tipo de Publ: Revisão
Metanálise
Revisão Sistemática
Responsável: BR1.1 - BIREME


  8 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-950735
Autor: Repsold, Lisa; Mqoco, Thandi; Wolmarans, Elize; Nkandeu, Sandra; Theron, Joji; Piorkowski, Tomek; du Toit, Peet; van Papendorp, Dirk; Joubert, Annie Margaretha.
Título: Ultrastructural changes of erythrocytes in whole blood after exposure to prospective in silico-designed anticancer agents: a qualitative case study
Fonte: Biol. Res;47:1-7, 2014. ilus, graf.
Idioma: en.
Resumo: BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female's erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C. RESULTS: No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress. CONCLUSIONS: From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome.
Descritores: Sulfonamidas/farmacologia
Simulação por Computador
Inibidores da Anidrase Carbônica/farmacologia
Eritrócitos/efeitos dos fármacos
Estradiol/análogos & derivados
Estrenos/farmacologia
Antineoplásicos/farmacologia
-Sulfonamidas/toxicidade
Sulfonamidas/farmacocinética
Temperatura
Inibidores da Anidrase Carbônica/farmacocinética
Disponibilidade Biológica
Microscopia Eletrônica de Varredura
Proteínas de Transporte/farmacologia
Proteínas de Transporte/farmacocinética
Anidrase Carbônica II/efeitos dos fármacos
Pesquisa Qualitativa
Eritrócitos/ultraestrutura
Estradiol/toxicidade
Estradiol/farmacologia
Estradiol/farmacocinética
Estrenos/farmacocinética
Descoberta de Drogas
Hemólise/efeitos dos fármacos
Antineoplásicos/farmacocinética
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Responsável: CL1.1 - Biblioteca Central


  9 / 161 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1151056
Autor: Franco, Juan Victor Ariel.
Título: Nueva interacción potencialmente peligrosa entre claritromicina y estatinas / Potentially dangerous interaction between clarithromycin and statins
Fonte: Evid. actual. práct. ambul;19(3):90-90, 2016.
Idioma: es.
Descritores: Claritromicina/efeitos adversos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Inibidores do Citocromo P-450 CYP3A/efeitos adversos
-Pirimidinas/metabolismo
Pirimidinas/uso terapêutico
Pirimidinas/farmacocinética
Rabdomiólise/induzido quimicamente
Sulfonamidas/metabolismo
Sulfonamidas/uso terapêutico
Sulfonamidas/farmacocinética
Ácidos Graxos Monoinsaturados/metabolismo
Ácidos Graxos Monoinsaturados/uso terapêutico
Ácidos Graxos Monoinsaturados/farmacocinética
Pravastatina/metabolismo
Pravastatina/uso terapêutico
Pravastatina/farmacocinética
Inibidores de Hidroximetilglutaril-CoA Redutases/metabolismo
Transportadores de Ânions Orgânicos
Transportadores de Ânions Orgânicos Sódio-Independentes/antagonistas & inibidores
Transportador 1 de Ânion Orgânico Específico do Fígado
Interações Medicamentosas
Injúria Renal Aguda/induzido quimicamente
Rosuvastatina Cálcica
Fluorbenzenos/metabolismo
Fluorbenzenos/uso terapêutico
Fluorbenzenos/farmacocinética
Membro 1B3 da Família de Transportadores de Ânion Orgânico Carreador de Soluto
Fluvastatina
Hiperpotassemia/induzido quimicamente
Indóis/metabolismo
Indóis/uso terapêutico
Indóis/farmacocinética
Limites: Humanos
Masculino
Feminino
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Comentário
Responsável: AR2.1 - Biblioteca Central


  10 / 161 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-896345
Autor: Abuowda, Yahia; Almeida, Raquel Sousa; Oliveira, Ana Alves; Pego, Petra; Santos, Cristina; Matos-Costa, João.
Título: Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome / Tratamento de úlceras digitais na esclerose sistêmica: série de casos de 13 doentes e análise crítica dos resultados
Fonte: Rev. Assoc. Med. Bras. (1992);63(5):422-426, May 2017. tab, graf.
Idioma: en.
Resumo: Summary Introduction: In systemic sclerosis (SSc), digital ulcers (DU) are debilitating and recurrent. They are markers of prognosis and are associated with disability and mortality. Treatment strategies have been developed to block the proposed mechanisms of this complication. Objective: Clinical description of a population of SSc patients with DU, treatment, complications and outcome. Method: Analysis of 48 SSc patients meeting 2013 ACR-EULAR criteria, followed between 1999-2015; 13 patients had DU. Treatment protocol applied included cycles of 21 days of alprostadil, which can be repeated in the absence of DU healing. After DU healing, bosentan was initiated. Results: DU healing was achieved with intravenous prostanoid in 12 patients; seven patients required repeated treatment for DU healing. Twelve patients were later treated with bosentan; three of them experienced recurrence of DU, while one was anti-B2-GPI positive. Four patients had soft tissue loss and three other suffered digital amputation, these being late diagnosis. Conclusion: Younger patients and early referrals had better outcomes. Endothelin receptor antagonist toxicity should be monitored, particularly in patients previously exposed to hepatotoxic drugs.

Resumo Introdução: As úlceras digitais (UD) são complicações incapacitantes e recorrentes, associadas a menor qualidade de vida e maior mortalidade na esclerose sistêmica (ES). O tratamento baseia-se em antagonizar os mecanismos fisiopatológicos em causa. Objetivo: Descrever uma amostra de doentes com diagnóstico de ES e UD, o tratamento, as complicações e os resultados clínicos. Método: Série de 48 casos diagnosticados com ES, critérios de classificação ACR-EULAR 2013, seguidos entre 1999 e 2015, dos quais 13 apresentavam UD. O protocolo aplicado incluía ciclos de 21 dias de alprostadil podendo ser repetidos no caso de não existir cicatrização. Nos casos em que houve cicatrização foi iniciado bosentano. Resultados: No tratamento das UD, 12 doentes realizaram prostaciclina endovenosa, com necessidade de tratamentos repetidos em sete doentes. Doze doentes foram posteriormente tratados com bosentano, com recorrência de UD em três doentes, um deles com presença de anti-B2-GPI. Quatro doentes ficaram com cicatrizes e em três houve amputação digital, sendo casos de diagnóstico tardio. Conclusão: Os doentes mais jovens tiveram melhores resultados, possivelmente em razão de melhorias globais nos cuidados de saúde prestados e de referenciação precoce. A toxicidade dos antagonistas dos receptores da endotelina deve ser monitorizada, sobretudo em doentes com exposição prévia a drogas hepatotóxicas.
Descritores: Escleroderma Sistêmico/complicações
Úlcera Cutânea/etiologia
Úlcera Cutânea/tratamento farmacológico
Sulfonamidas/uso terapêutico
Vasodilatadores/uso terapêutico
Alprostadil/uso terapêutico
Dedos
Antagonistas dos Receptores de Endotelina/uso terapêutico
-Úlcera Cutânea/patologia
Fatores de Tempo
Cicatrização/efeitos dos fármacos
Reprodutibilidade dos Testes
Resultado do Tratamento
Relação Dose-Resposta a Droga
Bosentana
Dermatoses da Mão/etiologia
Dermatoses da Mão/patologia
Dermatoses da Mão/tratamento farmacológico
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME



página 1 de 17 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde